Datavault AI (NASDAQ: DVLT) has signed a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding an existing technology license. The proposed deal, announced in a press release, would let Datavault AI retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board after closing. Datavault AI believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions.
The arrangement matters because it offers a capital-light path to monetizing Datavault AI’s health data technologies. By keeping its IP and collecting royalties rather than funding commercialization itself, the company could generate recurring revenue without bearing the full cost of bringing products to market. The expanded license would build on DataMEDS’ existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. That combination could position the companies in the emerging market for patient-authorized health data exchange, where control over sensitive information is a central concern.
The move is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI. For Datavault AI, the equity stake would provide strategic influence over how its licensed technologies are commercialized, while the board seat would give it a formal voice in DataMEDS’ direction. The letter of intent does not obligate either party to complete the transaction, so the proposed closing remains uncertain. Investors can view the full press release at https://ibn.fm/Q8IGK and learn more about Datavault AI at https://dvlt.ai. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
The announcement was distributed through DefenseWireNews, one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement, among other services. Full terms of use and disclaimers are available at https://www.DefenseWireNews.com/Disclaimer.
